{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"x_thread":8,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04556773\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DB-08","nct_id":"NCT04556773","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=db-08-nct04556773. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"DB-08","arms":[{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use","label":"Module 1: T-DXd + capecitabine","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use","label":"Module 2: T-DXd + durvalumab + paclitaxel","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use","label":"Module 3: T-DXd + capivasertib","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral","label":"Module 4: T-DXd + anastrozole","type":"EXPERIMENTAL"},{"description":"T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use","label":"Module 5: T-DXd + fulvestrant","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo Co., Ltd.","Daiichi Sankyo Company, Limited"],"completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":138,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Capivasertib","type":"DRUG"},{"name":"Anastrozole","type":"DRUG"},{"name":"Fulvestrant","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"}],"last_update":"2026-08-03","lead_sponsor":"AstraZeneca","official_title":"A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2023-08-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Occurrence of adverse events (AEs)- Part 1","timeFrame":"Up to follow-up period, approximately 24 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 1","timeFrame":"Up to follow-up period, approximately 24 months"},{"measure":"Occurrence of adverse events (AEs)- Part 2","timeFrame":"Up to follow-up period, approximately 24 months"},{"measure":"Occurrence of serious adverse events (SAEs)- Part 2","timeFrame":"Up to follow-up period, approximately 24 months"}],"references":[],"start_date":{"date":"2020-12-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04556773"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/db-08-nct04556773"}